Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 123 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Chlorothiazide Clear all
Completed Phase 4 Interventional

SMOOTH - Blood Pressure Control in Diabetic/Obese Patients

NCT00239538
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
telmisartan combined with hydrochlorothiazide (80/12.5 mg), valsartan combined with hydrochlorothiazide (160/12.5mg)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Early Phase 1 Interventional

N-of-1 Trials for Blood Pressure Medications in Adults

NCT02744456
View directory record Official record
Conditions
Hypertension, High Blood Pressure
Interventions
Losartan, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 4 Interventional

Vascular Improvement With Olmesartan Medoxomil Study

NCT00772499
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure, atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2008 · Synced Sep 7, 2026, 1:29 PM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 7, 2026, 1:29 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes

NCT00574834
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Ramipril, HCTZ-hydrochlorothiazide, Ramipril+HCTZ
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 4 Interventional

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

NCT00240448
View directory record Official record
Conditions
Hypertension
Interventions
telmisartan 80 mg/hydrochlorothiazide 25 mg, valsartan 160 mg/hydrochlorothiazide 25 mg, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 4 Interventional Results available

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients

NCT00744237
View directory record Official record
Conditions
Hypertension, Type 2 Diabetes Mellitus
Interventions
Nebivolol, Metoprolol ER, HCTZ
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
62
States / cities
Athens, Alabama • Huntsville, Alabama • Bell Gardens, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2011 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 3 Interventional

Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension

NCT00273299
View directory record Official record
Conditions
Hypertension
Interventions
valsartan plus hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
607 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Not applicable Interventional Results available

A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients

NCT00690521
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Treatment of Furosemide + Hydrochlorothiazide, Treatment of Furosemide + Metolazone
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 98 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 4 Interventional Results available

Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans

NCT00739596
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma

NCT06205407
View directory record Official record
Conditions
Healthy Participants
Interventions
Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris, Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

NCT00277472
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan/Hydrochlorothiazide, HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 4 Interventional Results available

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

NCT00926289
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan, Hydrochlorothiazide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
18
States / cities
Athens, Alabama • Mobile, Alabama • Lomita, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Salt Loading and Thiazide Intervention Study

NCT00896389
View directory record Official record
Conditions
Hypertension
Interventions
Salt loading, Hydrochlorothiazide (HCTZ)
Procedure · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 7, 2026, 1:29 PM EDT
Completed No phase listed Observational

Genetic Epidemiology of Responses to Antihypertensives

NCT00005520
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension
Interventions
Hydrochlorothiazide, Candesartan
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.

NCT00250562
View directory record Official record
Conditions
Hypertension
Interventions
valsartan plus hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

NCT00368277
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 4 Interventional Results available

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

NCT00673790
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol with concomitant losartan or lisinopril, HCTZ with concomitant losartan or lisinopril, Placebo with concomitant losartan or lisinopril
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
88
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 4 Interventional Results available

Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population

NCT00760266
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
55 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2011 · Synced Sep 7, 2026, 1:29 PM EDT
Terminated Early Phase 1 Interventional

Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes

NCT01804777
View directory record Official record
Conditions
Proteinuria, Hypertension, Type II Diabetes
Interventions
Amiloride, HCTZ
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 4 Interventional

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

NCT00185068
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide, Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
16
States / cities
Fort Lauderdale, California • Long Beach, California • Roseville, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2005 · Synced Sep 7, 2026, 1:29 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Chlorthalidone and HCTZ Impacts on Platelet Activation

NCT02100462
View directory record Official record
Conditions
Hypertension
Interventions
Chlorthalidone 12.5 mg, Hydrochlorothiazide 25 mg, Aspirin 81 mg
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 7, 2026, 1:29 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome

NCT01271374
View directory record Official record
Conditions
Hypertension
Interventions
amlodipine and olmesartan, losartan and HCTZ
Drug
Lead sponsor
InVasc Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Sep 7, 2026, 1:29 PM EDT
Completed Phase 4 Interventional Results available

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

NCT03115853
View directory record Official record
Conditions
High Blood Pressure
Interventions
Aliskiren 150 mg, Placebo, HCTZ, Aliskiren 300 mg
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Sep 7, 2026, 1:29 PM EDT